FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994326374> ?p ?o ?g. }

• W2994326374 abstract "Abstract Fludarabine is the most successful drug in patients with relapsed, progradient or refractory chronic lymphocytic leukemia (CLL). But also the use of fludarabine in primary therapy as an alternative to chlorambucil is in trial. Fludarabine induces higher response rates, but showed no improvement in overall survival. The reason for this clinical observation is unclear. In the present study we wanted to answer the question, if the induction of secondary resistance might be the cause for this contradiction. METHODS. Peripheral blood samples from 42 patients with B-CLL were tested in the in-vitro chemosensitivity-test DiSC-assay with 11 drugs. 10 patients had received no therapy before the time of carrying out the In vitro test. 23 patients were pre-treated with prednisone, 8 patient with fludarabine and 5 patients with vincristine. Most of the patients received more then one drug before testing. The chemosensitivity were determined using the LC90. RESULTS. The patients were divided into those who were pre-treated vs. not pre-treated with the fludarabine, prednisone or vincristine. The influences of pre-treatment to the sensitivity were analysed using the Mann-Whitney-U test for two independent groups. With fludarabine pre-treated patients had an significantly increased chemoresistance against fludarabine (2.4-fold; p=.004). The increase was also significant for bendamustin (4.4-fold), 2-CdA (3.4-fold), Gemcitabine (2.7-fold) and daunorubicin (1.5-fold). There was no significant influence observed onto the other drugs. Pre-treatment with vincristine or prednisone had no impact onto the chemosensitivity of any tested drug. INTERPRETATION AND CONCLUSIONS. The results of this study demonstrate the capability of fludarabine to increase the chemoresistance against various drugs in CLL. The use of fludarabine in primary therapy should be discussable. The fact that fludarabine induces higher response rates, without an improvement in overall survival, might be understandable if the fludarabine treatment induces a negative long-term effect. The widely increase of the chemoresistance is such a negative long-term effect. Based on the presented data, we postulate that fludarabine induces a so called secondary resistance by selecting leukemic cells with a lower chemosensitivity under treatment." @default.
• W2994326374 created "2019-12-13" @default.
• W2994326374 creator A5006268438 @default.
• W2994326374 creator A5057268503 @default.
• W2994326374 creator A5076077834 @default.
• W2994326374 date "2004-11-16" @default.
• W2994326374 modified "2023-10-16" @default.
• W2994326374 title "Fludarabine Treated CLL Patients Showed an Increased Chemoresistance Ex-Vivo." @default.
• W2994326374 doi "https://doi.org/10.1182/blood.v104.11.2791.2791" @default.
• W2994326374 hasPublicationYear "2004" @default.
• W2994326374 type Work @default.
• W2994326374 sameAs 2994326374 @default.
• W2994326374 citedByCount "0" @default.
• W2994326374 crossrefType "journal-article" @default.
• W2994326374 hasAuthorship W2994326374A5006268438 @default.
• W2994326374 hasAuthorship W2994326374A5057268503 @default.
• W2994326374 hasAuthorship W2994326374A5076077834 @default.
• W2994326374 hasConcept C126322002 @default.
• W2994326374 hasConcept C143998085 @default.
• W2994326374 hasConcept C203014093 @default.
• W2994326374 hasConcept C2776694085 @default.
• W2994326374 hasConcept C2776755627 @default.
• W2994326374 hasConcept C2777866208 @default.
• W2994326374 hasConcept C2777938653 @default.
• W2994326374 hasConcept C2778397455 @default.
• W2994326374 hasConcept C2778461978 @default.
• W2994326374 hasConcept C2778720950 @default.
• W2994326374 hasConcept C2779263901 @default.
• W2994326374 hasConcept C2779429289 @default.
• W2994326374 hasConcept C2780258809 @default.
• W2994326374 hasConcept C71924100 @default.
• W2994326374 hasConcept C90924648 @default.
• W2994326374 hasConcept C98274493 @default.
• W2994326374 hasConceptScore W2994326374C126322002 @default.
• W2994326374 hasConceptScore W2994326374C143998085 @default.
• W2994326374 hasConceptScore W2994326374C203014093 @default.
• W2994326374 hasConceptScore W2994326374C2776694085 @default.
• W2994326374 hasConceptScore W2994326374C2776755627 @default.
• W2994326374 hasConceptScore W2994326374C2777866208 @default.
• W2994326374 hasConceptScore W2994326374C2777938653 @default.
• W2994326374 hasConceptScore W2994326374C2778397455 @default.
• W2994326374 hasConceptScore W2994326374C2778461978 @default.
• W2994326374 hasConceptScore W2994326374C2778720950 @default.
• W2994326374 hasConceptScore W2994326374C2779263901 @default.
• W2994326374 hasConceptScore W2994326374C2779429289 @default.
• W2994326374 hasConceptScore W2994326374C2780258809 @default.
• W2994326374 hasConceptScore W2994326374C71924100 @default.
• W2994326374 hasConceptScore W2994326374C90924648 @default.
• W2994326374 hasConceptScore W2994326374C98274493 @default.
• W2994326374 hasLocation W29943263741 @default.
• W2994326374 hasOpenAccess W2994326374 @default.
• W2994326374 hasPrimaryLocation W29943263741 @default.
• W2994326374 hasRelatedWork W188945824 @default.
• W2994326374 hasRelatedWork W2013468325 @default.
• W2994326374 hasRelatedWork W2015120596 @default.
• W2994326374 hasRelatedWork W2270132162 @default.
• W2994326374 hasRelatedWork W2426644328 @default.
• W2994326374 hasRelatedWork W2797614161 @default.
• W2994326374 hasRelatedWork W2994326374 @default.
• W2994326374 hasRelatedWork W4237192281 @default.
• W2994326374 hasRelatedWork W4241881763 @default.
• W2994326374 hasRelatedWork W2486820453 @default.
• W2994326374 isParatext "false" @default.
• W2994326374 isRetracted "false" @default.
• W2994326374 magId "2994326374" @default.
• W2994326374 workType "article" @default.